A revision of the EU Public Procurement Directive (PPD) presents a critical opportunity to foster a sustainable, competitive, and resilient medicines supply. While the PPD (2014/24/EU) encourages a strategic approach through Most Economically Advantageous Tender (MEAT) criteria and limits reliance on price-only tenders, its adoption in medicines procurement remains limited.
VIA
Viatris
Company · United States · EU Transparency Register 940251520152-08
8
positions filed
in the 665 files tracked
6
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #248 by legislative files engaged, a count of participation, not a measure of influence.
1.2
declared lobbying FTE
self-declared
€300K+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2016
in the register since
Declares membership of
- Medicines for Europe (MfE) https://www.medicinesforeurope.com/
- Amcham EU https://www.amchameu.eu/
- Pharma Deutschland Brussels Office: https://www.pharmadeutschland.de/
- US Chamber of Commerce: https://www.uschamber.com/
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Registered as
- BGP Products Operations GmbH – a Viatris Company (Viatris)
- Head office
- Steinhausen, Switzerland
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Viatris in PolicySpeak: request access →
Work at Viatris? so we know who speaks for it.
Their record over time
Viatris filed 8 positions between 27 Apr 2021 and 26 Jan 2026, across 6 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2021 · 1 filed2022 · 1 filed2023 · 4 filed2025 · 1 filed2026 · 1 filed
What they argued
A revision of the EU Public Procurement Directive (PPD) presents a critical opportunity to ensure a sustainable, competitive, and resilient medicines supply.The European Commission (EC) should consider the following evidence-based reforms: 1.
Viatris is a global healthcare company, supplying 36.8 billion doses of medicine annually in Europe. Our portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning generics, complex generics, and branded medicines.
Viatris is a global healthcare company, uniquely positioned to bridge the traditional divide between generics and brands, with a European portfolio comprising more than 1,400 approved molecules across all major therapeutic areas. Annually, Viatris supplies 36.8 billion doses of medicine in Europe, contributing significantly to equitable access to medicines in the region.
Viatris is a global healthcare company, uniquely positioned to bridge the traditional divide between generics and brands, with a European portfolio comprising more than 1,400 approved molecules across all major therapeutic areas. Annually, Viatris supplies 36.8 billion doses of medicine in Europe, contributing significantly to access to medicines in the region.
VIATRIS is a new healthcare company, formed in 2020 through the combination of Mylan and Upjohn. We are committed to providing access to medicines, advancing sustainable operations and developing innovative solutions to improve patient outcomes.
VIATRIS is committed to providing access to medicines, advancing sustainable operations, and developing innovative solutions to improve patient outcomes. Our portfolio comprises more than 1,400 molecules across major therapeutic areas including brand medicines, generics, OTC medicines, and APIs.
Viatris is a global healthcare company with a European portfolio comprising more than 1,400 approved molecules across a wide range of therapeutic areas, spanning generics, complex generics and branded medicines. Annually,Viatris supplies 36.8 billion doses of medicine in Europe. We are fully committed to protecting the environment, while safeguarding a reliable supply of medicines.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Viatris next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 260.
Is this your organization?
Everything on this page comes from Viatris’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.